AJ-GEMCITABINE POWDER FOR SOLUTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

GEMCITABINE (GEMCITABINE HYDROCHLORIDE)

Dostupné s:

AGILA JAMP CANADA INC

ATC kód:

L01BC05

INN (Mezinárodní Name):

GEMCITABINE

Dávkování:

2G

Léková forma:

POWDER FOR SOLUTION

Složení:

GEMCITABINE (GEMCITABINE HYDROCHLORIDE) 2G

Podání:

INTRAVENOUS

Jednotky v balení:

100ML

Druh předpisu:

Prescription

Terapeutické oblasti:

ANTINEOPLASTIC AGENTS

Přehled produktů:

Active ingredient group (AIG) number: 0133122004; AHFS:

Stav Autorizace:

CANCELLED PRE MARKET

Datum autorizace:

2015-11-03

Charakteristika produktu

PRODUCT MONOGRAPH
PR
AJ-GEMCITABINE
GEMCITABINE FOR INJECTION, USP
200 MG, 1 G AND 2 G PER VIAL
38 MG/ML GEMCITABINE (AS GEMCITABINE HYDROCHLORIDE)
STERILE LYOPHILIZED POWDER
ANTINEOPLASTIC AGENT
DATE OF PREPARATION:
AGILA JAMP CANADA INC.
1380 – 203 Newton
Boucherville, Québec
Canada J4B 5H2
July 18, 2013
SUBMISSION CONTROL NUMBER: 165924
AJ-GEMCITABINE Product Monograph
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................
20
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
........................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
24
STORAGE AND STABILITY
.................................................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 26
PART II: SCIENTIFIC INFORMATION
...............................................................................
27
PHARMACEUTICAL INFORMATION
.................................................................................
27
CLINICAL TRIALS
......